Non-Steroidal Anti-Inflammatory Drugs Market Skyrockets: Witness Impressive US$ 28.7 billion by 2030 and Striking CAGR of 6.0% - By PMI
November 09, 2023 08:30 ET
|
PMI
Covina, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Report Overview of Non-Steroidal Anti-Inflammatory Drugs Market: Non-Steroidal Anti-Inflammatory Drugs, commonly known as NSAIDs, are a class of...
Spherix Global Insights Amplifies the Lupus Patient Voice, Highlighting the Lengthy and Challenging Journey to Diagnosis and Treatment
November 08, 2023 15:37 ET
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 08, 2023 (GLOBE NEWSWIRE) -- [Exton PA, November 8, 2023] — Spherix Global Insights recently conducted research with 306 Systemic Lupus Erythematosus (SLE) patients,...
In a Push to Limit Use of Glucocorticoids, US and EU5 Rheumatologists are Increasingly Turning to GSK’s Benlysta and AstraZeneca’s Saphnelo for the Treatment of Moderate-to-Severe Systemic Lupus Erythematosus, According to Spherix Global In
October 04, 2023 03:00 ET
|
Spherix Global Insights
Exton, Pennsylvania, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Prior to the initial approval of Benlysta in 2011, systemic lupus erythematosus (SLE) patients and prescribers had limited options for the...
An Old Dog with a New Trick… Ellodi’s APT-1011 Promises EoE Patients a Convenient and Potent Treatment Alternative
August 15, 2023 15:40 ET
|
Spherix Global Insights
Exton, Pennsylvania, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Since launching in May 2022, Sanofi/Regeneron’s Dupixent has been well received by gastroenterologists and allergists as an advancement for...
Market Access Issues Hindering Specialists’ Use of Advanced Systemics in Lupus Nephritis
July 27, 2023 16:00 ET
|
Spherix Global Insights
Exton, Pennsylvania, July 27, 2023 (GLOBE NEWSWIRE) -- While the approvals of GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have provided rheumatologists and nephrologists with...
Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors
May 30, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., May 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform
April 18, 2023 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Ad Scientiam Launches Programs to Develop Digital Biomarkers for Chronic Neurological Diseases
February 28, 2023 08:00 ET
|
Ad Scientiam
PARIS, FRANCE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- On Rare Disease Day, Ad Scientiam, a leader in digital biomarkers, announced the launch of two ambitious programs to develop and validate novel...
Ad Scientiam Launches Programs to Develop Digital Biomarkers for Chronic Neurological Diseases
February 28, 2023 08:00 ET
|
Ad Scientiam
PARIS, FRANCE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- On Rare Disease Day, Ad Scientiam, a leader in digital biomarkers, announced the launch of two ambitious programs to develop and validate novel...
Pharmerging Market is estimated to be US$ 4426.72 billion by 2030 with a CAGR of 16.5% during the forecast period - By PMI
July 04, 2022 09:45 ET
|
PMI
Covina, July 04, 2022 (GLOBE NEWSWIRE) -- Particularly in the worldwide emerging economies, the Pharmerging industry is growing significantly. Some of the main drivers of this market's expansion are...